Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study
A group of 20 patients with advanced medullary (MTC) or differentiated thyroid carcinoma (DTC) received a combination chemotherapy of doxorubicin (50 mg/m2), cisplatin (60 mg/m2) and vindesine (3 mg/m2). In the 18 (10 MTC, 8 DTC) evaluable patients only 1 partial remission (in a patient with MTC) and 3 minor responses (in 3 patients with DTC) were observed. These responses lasted for 15, 9, 13, and 22 months, respectively. Three MTC patients suffered from progressive disease and "no change" was seen in the other 11 patients. Toxicity, including 1 severe case of cardiomyopathy, was considerable. Thus, the combination chemotherapy of doxorubicin, cisplatin and vindesine has failed to prove superior to the commonly applied doxorubicin monotherapy in patients with advanced medullary or differentiated thyroid carcinoma.
Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil
A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma
Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide
Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection
Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection
Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid
Changes of regulatory T and B cells in patients with papillary thyroid carcinoma after 131I radioablation: a preliminary study
Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma
Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors
Investigating the expression and promoter methylation of RET gene in patients with medullary thyroid cancer with unmutated RET
Drug therapy of endocrine neoplasms. Part I: Thyroid neoplasms, adrenal neoplasms and parathyroid neoplasms
Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas.
Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.